Form 4: Natera Executive Sells 3,000 Shares Under 10b5-1 Plan

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 3,000 shares of common stock for approximately $500,000 through a pre-arranged 10b5-1 trading plan.

Summary

• Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), sold a total of 3,000 shares of the company's common stock.
• The sales occurred on September 2, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024.
• The shares were sold in three separate transactions at weighted average prices ranging from $165.6862 to $167.7145 per share.
• Following these transactions, Mr. Moshkevich beneficially owns 120,859 shares of Natera common stock.

Sentiment

Score: 5

Explanation: The sale of shares by an insider, even under a 10b5-1 plan, is generally neutral to slightly negative as it reduces insider ownership. However, the pre-planned nature mitigates concerns about opportunistic selling.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and automated transaction rather than a discretionary sale based on new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general perception of insider selling.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing reports a routine insider stock transaction and does not provide information directly related to broader industry trends or competitor activities within the clinical diagnostics sector.

Comparison to Industry Standards

• This filing details an insider stock transaction and does not contain information suitable for comparison to global industry benchmarks, specific comparable companies, projects, or results.

Related Party Transactions

• Solomon Moshkevich, an officer of Natera, Inc., sold shares of the company's common stock, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, though the 10b5-1 plan mitigates concerns about opportunistic selling. The transaction itself does not directly impact employees, customers, suppliers, or creditors.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The insider sale by a company executive, while reducing their direct equity stake, was conducted under a pre-arranged 10b5-1 trading plan. This suggests a planned liquidity event rather than a reaction to new negative information, thus not warranting a change in investment thesis based solely on this filing. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Natera, NTRA, Insider Sale, Form 4, Solomon Moshkevich, 10b5-1 Plan, Stock Transaction, Clinical Diagnostics